BSX stock forecast, quote, news & analysis
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts... Show more
Boston Scientific (BSX) Stock Analysis: Growth Headwinds and a Deep Drawdown Reshape the Medtech Narrative
Key Takeaways
- Boston Scientific shares traded near $44 in mid-July 2026, down approximately 60% from the 52-week high of $109.50 reached in September 2025.
- Management lowered full-year 2026 organic growth guidance to 6.5%–8% from a prior range of 10%–11%, citing softness in Watchman, electrophysiology, and urology segments.
- The company announced a roughly $14.5 billion acquisition of Penumbra, its largest deal in two decades, adding neurovascular and thrombectomy technologies while increasing leverage.
- A $5 billion share repurchase authorization and insider buying by multiple directors signal that leadership views the stock as undervalued.
- Q2 2026 earnings are scheduled for July 29, with analysts projecting adjusted EPS of $0.83 on revenue of approximately $5.37 billion.
- Wall Street maintains a consensus "Moderate Buy" rating with an average price target near $80, implying substantial upside from current levels — though estimate cuts have been frequent.
Current Market Snapshot
Boston Scientific Corporation (BSX) enters the second half of 2026 under considerable pressure. The stock has retreated roughly 60% from its September 2025 peak of $109.50, and the 50-day moving average of $48.18 sits well above the recent trading range near $44. The 200-day moving average of $65.87 underscores how far the stock has fallen from levels that prevailed earlier in the year. Trading volumes have periodically spiked above the 90-day average during selloffs, indicating active repositioning by institutional investors. Despite the selloff, 89% of shares remain held by institutions — including major holders such as Vanguard, State Street, Capital World Investors, and Norges Bank — reflecting deep-rooted institutional conviction in the company's long-term franchise value. With a market capitalization of roughly $65 billion and a forward P/E near 13, the stock is pricing in a significant deceleration relative to the premium multiples it commanded throughout 2024 and early 2025.
Boston Scientific (BSX) Business Overview and Competitive Position
Boston Scientific is a global medical technology leader headquartered in Marlborough, Massachusetts. Founded in 1979, the company develops, manufactures, and markets a diversified portfolio of devices used in minimally invasive procedures across interventional cardiology, electrophysiology, endoscopy, urology, neuromodulation, and peripheral interventions. Among its flagship franchises is the Watchman left atrial appendage closure device for atrial fibrillation patients, as well as the FARAPULSE pulsed field ablation system, which has been a major growth engine in the electrophysiology market. The company also competes in structural heart, interventional oncology, and gastrointestinal endoscopy, and its pending acquisition of Penumbra would extend its reach into neurovascular stroke care. BSX's competitive advantages include deep physician relationships, a global commercial infrastructure spanning more than 100 countries, robust clinical evidence generation, and a pipeline of next-generation products across multiple high-growth procedural categories.
Recent Developments Driving BSX
The most consequential catalyst in recent weeks was the guidance reset communicated at Bernstein's Strategic Decisions Conference in late May. CEO Michael Mahoney disclosed that Watchman heart implant sales would be flat sequentially in both Q2 and Q3, while full-year organic growth guidance was cut to 6.5%–8% from an earlier 10%–11% range. Management also cited declining standalone procedure volumes since February and softer demand in electrophysiology and urology — segments that had been expected to contribute meaningfully to growth. The market reaction was swift and severe, with shares falling roughly 12% in a single session.
Compounding the organic growth concerns is the company's agreement to acquire PEN (Penumbra) in an approximately $14.5 billion cash-and-stock transaction, with roughly $11 billion funded through cash and new debt. The deal represents BSX's largest acquisition in two decades and adds high-growth neurovascular and thrombectomy capabilities, but it also increases leverage and arrives when the core business is navigating a growth slowdown. Analysts at Jefferies cut their BSX price target from $100 to $67, while Mizuho trimmed its target from $90 to $70 — both maintaining Buy-equivalent ratings but acknowledging the reset in near-term expectations.
Additional headwinds include voluntary Class II recalls of CRE and CRE Pro Wireguided endoscopy devices related to potential sterile packaging breaches, and a downgrade from Weiss Ratings to "Sell." On the positive side, the board authorized a $5 billion share repurchase program, and multiple directors — including David Habiger, Cheryl Pegus, and Edward Ludwig — purchased shares in May at prices between $55 and $57, well above current levels. The Q1 2026 earnings report delivered $0.80 in adjusted EPS on $5.20 billion in revenue, topping consensus estimates, and organic growth of 9.4% exceeded guidance despite emerging headwinds.
Trending AI Robots
Investors navigating volatile names like Boston Scientific are increasingly turning to data-driven tools for objective decision support. Tickeron's Trending AI Robots page curates a select group of top-performing AI trading bots from a universe of hundreds that actively trade thousands of tickers across equities, ETFs, and cryptocurrencies. Each bot operates on a distinct algorithmic strategy — spanning swing trading, trend following, breakout detection, and mean reversion — with varying timeframes and performance metrics displayed transparently. Only the most relevant and consistently strong-performing bots are surfaced in this curated section, giving traders a filtered view of AI-driven signals worth monitoring. Exploring the Trending AI Robots page can help investors identify automated strategies aligned with current market conditions and their individual trading objectives.
2026 Outlook and What Investors Should Watch
The most immediate event on the calendar is the Q2 2026 earnings report scheduled for July 29, before the market opens. Analysts expect adjusted EPS of $0.83 and revenue near $5.37 billion, and investors will scrutinize whether Watchman volumes have stabilized and whether the broader electrophysiology and urology softness persisted through the quarter. The Penumbra acquisition is expected to close in the second half of 2026, and integration execution — including balance sheet management, revenue synergy realization, and cultural alignment — will be a persistent focus for the remainder of the year.
Longer-term, the CHAMPION-AF clinical trial results, which met primary and secondary endpoints and were presented at the American College of Cardiology conference, could support a first-line indication for Watchman and unlock a significantly larger addressable market. Product launches including the FARAWAVE NAV catheter, Bolt intravascular lithotripsy system, and EMPOWER leadless pacemaker are expected to contribute to the second-half growth narrative. Macroeconomic crosscurrents — including tariff impacts on medical device supply chains, currency fluctuations, and hospital capital spending trends — remain relevant risk factors. With consensus analyst price targets clustering between $65 and $90, the market is pricing in a cautious but not catastrophic outlook, and the trajectory of estimate revisions through the back half of 2026 will be pivotal for sentiment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
BSX's Indicator enters downward trend
The Aroon Indicator for BSX entered a downward trend on July 20, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 126 similar instances where the Aroon Indicator formed such a pattern. In of the 126 cases the stock moved lower. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BSX as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BSX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BSX's RSI Indicator exited the oversold zone, of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 52 cases where BSX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for BSX just turned positive on June 23, 2026. Looking at past instances where BSX's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BSX advanced for three days, in of 340 cases, the price rose further within the following month. The odds of a continued upward trend are .
BSX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.482) is normal, around the industry mean (10.868). P/E Ratio (18.071) is within average values for comparable stocks, (64.904). Projected Growth (PEG Ratio) (0.535) is also within normal values, averaging (3.960). BSX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.017). P/S Ratio (3.132) is also within normal values, averaging (24.894).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BSX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of medical devices
Industry MedicalNursingServices